Related Experiment Video
Updated: Jun 28, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Intravenous gammaglobulin treatment in HIV-1 infection
Avi Deener1, Ami Mehra, Larry Bernstein
1Department of Pediatrics, Division of Allergy and Immunology, Albert Einstein College of Medicine and Montefiore Hospital Medical Center, 1525 Blondell Avenue, Bronx, NY 10461, USA.
Abstract:
The two main indications for the use of intravenous gammaglobulin--antibody replacement therapy and immunomodulation--are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.
Related Concept Videos
Cryptococcal Meningitis
Inhibitors of Viral Protein Synthesis
Sexually Transmitted Infections
Venous Thrombosis III: Interprofessional Care
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles

